Article Text

Download PDFPDF

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Routine infant vaccination with the seven-valent pneumococcal conjugate vaccine was introduced in the USA in 2002. National sample data for the years 1997–99 and 2001–04 (Lancet 2007;369:1179–86; see also Comment, ibid: 1144–5) have shown the extent of the decline in hospital admissions of young children for pneumonia since then. Among children less than 2 years old hospital admissions for pneumonia of any cause fell by 39% by 2004. The vaccine prevented about 41 000 such hospital admissions in 2004 and admissions for pneumococcal pneumonia fell by 65%. Reductions of 17–18% in admissions of older children for pneumonia of any cause did not reach statistical significance but there was a significant 26% reduction among young adults aged 18–39 years, attributed to a herd immunity effect of the vaccine. As a control measure it was noted that hospital admissions for dehydration did not change during the study period.

In the UK neonatal screening for cystic fibrosis could be cost-saving. Data from the UK cystic fibrosis database were analysed and yearly treatment costs analysed for 184 patients diagnosed by neonatal screening and 950 patients diagnosed clinically in 2002 (Lancet 2007;369:1187–95; see also Comment: ibid: 1146–7). Median and mean yearly costs were significantly lower in the neonatal screening group (US $352 and $7228) than in the clinically diagnosed group (US $2442 and $12 008). …

View Full Text